Press release
Global Primary Sclerosing Cholangitis Market Industry Outlook to 2026 With Acorda Therapeutics, Inc. (US), Gilead Sciences, Inc. (US), NGM Biopharmaceuticals (US), Intercept Pharmaceuticals & Others
Ask For Complimentary Sample PDF | Request At https://databridgemarketresearch.com/request-a-sample/?dbmr=global-primary-sclerosing-cholangitis-market
This Primary Sclerosing Cholangitis market report is a total overview of the market that covers various aspects of product definition, market segmentation based on various parameters, and the existing vendor landscape. This market research report is a scrupulous analysis of current scenario of the market, which covers several market dynamics. This report motivates clients to seek new business ventures and evolve better. This Primary Sclerosing Cholangitis market study also estimates the market status, market share, growth rate, sales volume, future trends, market drivers, market restraints, revenue generation, opportunities and challenges, risks and entry barriers, sales channels, and distributors.
This Primary Sclerosing Cholangitis market research report identifies and analyses the up-and-coming trends along with major drivers, restraints, challenges and opportunities in the market for pharmaceutical industry. This market research report deals with an array of important market related aspects which can be listed as follows; market size estimations, company and market best practices, entry level strategies, market dynamics, positioning, segmentations, competitive landscaping and benchmarking, opportunity analysis, economic forecasting, industry-specific technology solutions, roadmap analysis, and in-depth benchmarking of vendor offerings. Primary Sclerosing Cholangitis is the most appropriate, realistic and admirable market research report delivered with a supreme devotion and comprehension of business needs.
Key Market Competitors:
Few of the major competitors currently working in the primary sclerosing cholangitis market are Acorda Therapeutics, Inc. (US), Gilead Sciences, Inc. (US), NGM Biopharmaceuticals (US), Intercept Pharmaceuticals, Inc. (US), Dr. Falk Pharma GmbH (Germany), ALLERGAN (Ireland), Takeda Pharmaceutical Company Limited. (Japan), DURECT CORPORATION (US), Conatus Pharmaceuticals, Inc. (US), Sirnaomics, Inc. (US), and HighTide Therapeutics Inc. (China), Glenmark (India), Impax Laboratories, LLC (US), Mylan N.V. (US), Teva Pharmaceuticals Industries Ltd. (Israel) and few among others.
Market Drivers
Rise in incidence and prevalence rate of liver failure and bile cancer associated with PSC.
Large No. of pipeline molecules is expected to drive the growth of the market.
Market Restraints
Withdrawal of novel molecules from late stage clinical trials will restrain the growth of the market.
Organ transplantation remains the alternative which is associated with many risk factors like relapse of the disease.
Lack of skilled expertise in remote areas
Fewer Government initiatives taken in this direction.
Table of Contents
Introduction
1.Market Segmentation
2.Market Overview
3.Executive Summary
4.Premium Insights
5.Global, By Component
6.Product Type
7.Delivery
8.Industry Type
9.Geography
Get detailed toc @ https://databridgemarketresearch.com/toc/?dbmr=global-primary-sclerosing-cholangitis-market
Segmentation:
By Type
Classic PSC
Small-duct PSC
PSC associated with autoimmune hepatitis
By Treatment Type
Ursodeoxycholic acid
Obeticholic Acid
Methotrexate
Corticosteroids
Others
By Symptom Control
Antihistamines
Cholestyramine
Antibacterials
Opioid Antagonists
Colestipol
Others
By End- User
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
By Geography
North America
South America
Europe
Asia-Pacific
Middle East & Africa
Key Developments in the Market:
On 19th January, 2016, Acorda Therapeutics, Inc. announced that it entered into an agreement to acquire Biotie Therapies Corp. According to the agreement, the company will acquire the four pipeline products that include BTT1023, a fully human monoclonal antibody in Phase 2 development for treatment of primary sclerosing cholangitis (PSC) which will help company to grow.
On 27th March, 2019, Gilead Sciences, Inc. announced the company’s research and development programs in primary sclerosing cholangitis (PSC) will be presented at The International Liver Congress™ 2019 in Vienna. Currently the novel molecule, Cilofexor has not get the approval but once it gets approval it will generate the revenue for the company and contribute towards the growth of the market.
Competitive Analysis:
Global primary sclerosing cholangitis market is highly fragmented and the major players have used various strategies such as new product launches, expansions, agreements, joint ventures, partnerships, acquisitions, and others to increase their footprints in this market. The report includes market shares of primary sclerosing cholangitis market for global, Europe, North America, Asia-Pacific, South America and Middle East & Africa.
Inquiry For Customize Report With Discount at : https://databridgemarketresearch.com/inquire-before-buying/?dbmr=global-primary-sclerosing-cholangitis-market
Contact:
Data Bridge Market Research
Tel: +1-888-387-2818
Email: Sopan.gedam@databridgemarketresearch.com
About Us:
Data Bridge set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge endeavors to provide appropriate solutions to the complex business challenges and initiates an effortless decision-making process.
Data bridge is an aftermath of sheer wisdom and experience which was formulated and framed in the year 2015 in Pune. We ponder into the heterogeneous markets in accord with our clients needs and scoop out the best possible solutions and detailed information about the market trends. Data Bridge delve into the markets across Asia, North America, South America, Africa to name few.
Data Bridge adepts in creating satisfied clients who reckon upon our services and rely on our hard work with certitude. We are content with our glorious 99.9 % client satisfying rate.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Global Primary Sclerosing Cholangitis Market Industry Outlook to 2026 With Acorda Therapeutics, Inc. (US), Gilead Sciences, Inc. (US), NGM Biopharmaceuticals (US), Intercept Pharmaceuticals & Others here
News-ID: 1791667 • Views: …
More Releases from Data Bridge Market Research
Precision gearbox market grow at a CAGR of 9.1% in the forecast period of 2022 t …
Precision gearbox market is expected to gain market growth in the forecast period of 2022 to 2029. Data Bridge Market Research analyses the market to reach at an estimated value of USD 5.9 billion by 2029 and grow at a CAGR of 9.1% in the above-mentioned forecast period.
Market Overview
This precision gearbox market report provides details of new recent developments, trade regulations, import export analysis, production analysis, value chain optimization, market…
Neuropathic Pain Market is expected to undergo a CAGR of 9.2% during the forecas …
Data Bridge Market Research analyses that the global neuropathic pain market, which was USD 5.86 billion in 2023, is expected to reach USD 11.86 billion by 2031, and is expected to undergo a CAGR of 9.2% during the forecast period of 2024 to 2031.
Market Overview
Neuropathic pain is a type of chronic pain caused by damage or dysfunction of the nervous system. It often presents as burning, shooting, or electric shock-kind…
Radiology market registering a CAGR of 6.20% during the forecast period of 2022- …
Radiology market was valued at USD 26.6 billion in 2021 and is expected to reach USD 43.04 billion by 2029, registering a CAGR of 6.20% during the forecast period of 2022-2029. The market report curated by the Data Bridge Market Research team includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Market Overview
Radiology (also referred as diagnostic imaging) includes multiple tests are included in the process, which…
Cervical Retractors Market Size, Share, Trends, Key Drivers, Growth and Opportun …
Global Cervical Retractors Market report focuses on several essential parameters related to the market that includes but are not limited to a competitive landscape, brief segmentation and industrial infrastructure. This marketing report offers an in-depth overview of product specification, technology, product type and production analysis considering major factors such as revenue, cost, and gross margin. Cervical Retractors market is supposed to grow during the forecast period due to growing demand…
More Releases for Primary
Primary Prevention of Cancer
Primary prevention of cancer aims to prevent the disease before it ever occurs. More than 4 in 10 cancers as well as cancer deaths are linked to modifiable risk factors that can be altered as part of primary cancer prevention. The modifiable risk factors for primary prevention include:
1. Cigarette smoking: Smoking causes almost all cases of lung cancer and accounts for 30% of all cancer deaths. Prevention strategy for this risk…
Global Primary Sclerosing Cholangitis Market
The Primary Sclerosing Cholangitis report offers insights into vital aspects like growth,CAGR value, market share and revenue analysis. It evaluates the growth opportunities, threats, market drivers and risks involved. understand the market competition by analyzing the top vendors, with their market profile, revenue, profits, import-export details, and market share. it states the pricing structure, import-export details, supply chain analysis, SWOT analysis to facilitate the key decision-making process. This report helps…
Primary Lithium Battery (Primary Lithium Batteries) Industry Analysis by 2025: …
In its recently published report, QY Research has provided unique insights about global Primary Lithium Battery (Primary Lithium Batteries) market for the given period. One of the main objectives of this report is to categorize the various dynamics of the market and to offer latest updates such as mergers and acquisitions, various technological developments, new entrants in the market, which make an impact on different segments of the global Primary…
Primary Cells And Primary Batteries Market Analysis by Production Capacity, Dyna …
This report helps to analyze competitive developments such as joint ventures, strategic alliances, mergers and acquisitions, new product developments, and research and developments in the Global Primary Cells And Primary Batteries market.
Description
The Global Primary Cells And Primary Batteries Market report offers a comprehensive evaluation of the Global Primary Cells And Primary Batteries industry. This report evaluates the Global market for " Global Primary Cells And Primary Batteries".
The Global Primary Cells…
Primary Immunodeficiency Diseases Market: Key Insights
With only a handful of companies enjoying the major share of the revenue pie, the global primary immunodeficiency diseases (PIDD) market exhibits a consolidated vendor landscape. As per Transparency Market Research (TMR), CSL Behring LLC and Grifols S.A. emerged dominant in the market with a share of 60.5% in 2014. Baxter International, Inc. and Octapharma AG are other prominent enterprises operating in the global PIDD market.
These companies have been…
Global Primary Biliary Cholangitis Treatment Market is Driven by Rise in Inciden …
Primary biliary cholangitis, previously known as primary biliary cirrhosis, is a rare chronic liver disease, primarily characterized by destruction of the bile ducts which transport bile acid out of the liver. Although the primary cause of the disease has not yet been elucidated, research across the world has attributed it to be autoimmune in nature. The progress of this disease results in the harmful accumulation of bile acid, which causes…
